BOSTON SCIENTIFIC ($BSX) posted quarterly earnings results on Wednesday, October 22nd. The company reported earnings of $0.75 per share, beating estimates of $0.72 by $0.03. The company also reported revenue of $5,065,000,000, beating estimates of $5,016,949,618 by $48,050,382.
You can see Quiver Quantitative's $BSX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BOSTON SCIENTIFIC Insider Trading Activity
BOSTON SCIENTIFIC insiders have traded $BSX stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 4 sales selling 328,886 shares for an estimated $33,903,109.
- JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 7 sales selling 256,372 shares for an estimated $26,574,358.
- ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) has made 0 purchases and 2 sales selling 34,627 shares for an estimated $3,578,501.
- EDWARD J LUDWIG has made 0 purchases and 2 sales selling 8,000 shares for an estimated $842,488.
- VANCE R BROWN (SVP, GC and Corp. Secretary) sold 4,826 shares for an estimated $513,582
- JOHN BRADLEY SORENSON (EVP, Global Operations) sold 4,572 shares for an estimated $477,956
- YOSHIAKI FUJIMORI sold 2,901 shares for an estimated $310,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BOSTON SCIENTIFIC Hedge Fund Activity
We have seen 874 institutional investors add shares of BOSTON SCIENTIFIC stock to their portfolio, and 654 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 20,286,637 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $2,178,987,680
- EDGEWOOD MANAGEMENT LLC added 6,951,450 shares (+inf%) to their portfolio in Q2 2025, for an estimated $746,655,244
- JPMORGAN CHASE & CO removed 5,862,792 shares (-18.6%) from their portfolio in Q2 2025, for an estimated $629,722,488
- BLACKROCK, INC. added 5,016,674 shares (+3.5%) to their portfolio in Q2 2025, for an estimated $538,840,954
- VOYA INVESTMENT MANAGEMENT LLC removed 4,362,310 shares (-49.9%) from their portfolio in Q3 2025, for an estimated $425,892,325
- MILLENNIUM MANAGEMENT LLC removed 3,708,137 shares (-44.4%) from their portfolio in Q2 2025, for an estimated $398,290,995
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 3,662,461 shares (-22.2%) from their portfolio in Q2 2025, for an estimated $393,384,936
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BOSTON SCIENTIFIC Government Contracts
We have seen $19,411,547 of award payments to $BSX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- Y90 GLASS MICROSPHERES: $1,197,000
- THERASPHERE Y-90: $963,835
- THERASPHERE Y90 TREATMENTS.: $720,000
- Y90 THERASPHERE: $675,325
- YTTRIUM-90 THERASPHERES: $532,500
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BOSTON SCIENTIFIC Congressional Stock Trading
Members of Congress have traded $BSX stock 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 07/31, 06/26, 06/11, 05/13, 04/28.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BOSTON SCIENTIFIC Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 10/17/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Baird issued a "Outperform" rating on 10/01/2025
- Leerink Partners issued a "Outperform" rating on 10/01/2025
- Canaccord Genuity issued a "Buy" rating on 10/01/2025
- Truist Securities issued a "Buy" rating on 10/01/2025
- BTIG issued a "Buy" rating on 10/01/2025
To track analyst ratings and price targets for BOSTON SCIENTIFIC, check out Quiver Quantitative's $BSX forecast page.
BOSTON SCIENTIFIC Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 15 analysts offer price targets for $BSX in the last 6 months, with a median target of $125.0.
Here are some recent targets:
- Mike Matson from Needham set a target price of $121.0 on 10/17/2025
- Vijay Kumar from Evercore ISI Group set a target price of $110.0 on 10/07/2025
- Matt Miksic from Barclays set a target price of $136.0 on 10/02/2025
- David Rescott from Baird set a target price of $128.0 on 10/01/2025
- Marie Thibault from BTIG set a target price of $132.0 on 10/01/2025
- William Plovanic from Canaccord Genuity set a target price of $132.0 on 10/01/2025
- Richard Newitter from Truist Securities set a target price of $129.0 on 10/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
